EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY 4.0

A Randomised Controlled Trial of SFX-01 After Subarachnoid Haemorrhage — The SAS Study

Ardalan Zolnourian, Patrick Garland, Patrick Holton, Mukul Arora, Jonathan Rhodes, Christopher Uff, Tony Birch, David Howat, Stephen Franklin, Ian Galea, Diederik Bulters

Translational Stroke Research · 2025

DOI: 10.1007/s12975-024-01278-1 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Translational Stroke Research, 2025. Verfasst von Ardalan Zolnourian und 10 weiteren Autor:innen. Beteiligte Einrichtung: Neurosurgery, University Hospital Southampton, Southampton, UK. Hauptthemen laut MEDLINE: Subarachnoid Hemorrhage, Sulfoxides, Isothiocyanates. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Evgen Pharma.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

SFX-01 is a novel drug for clinical delivery of sulforaphane (SFN). SFN is a potent nuclear factor erythroid 2-related factor 2 activator that reduces inflammation and oxidation, improving outcomes after subarachnoid haemorrhage (SAH) in animal models. This was a multi-centre, double-blind, placebo-controlled, parallel-group randomised clinical trial to evaluate the safety, pharmacokinetics and efficacy of 28 days of SFX-01 300 mg BD in patients aged 18–80 with spontaneous SAH and high blood load on CT. Primary outcomes were (1) safety, (2) plasma and CSF SFN and metabolite levels and (3) vasospasm on transcranial doppler ultrasound. Secondary outcomes included CSF haptoglobin and malondialdehyde and clinical outcome on the modified Rankin Scale (mRS) and SAH outcome tool (SAHOT). A total of 105 patients were randomised (54 SFX-01, 51 placebo). There were no differences in adverse events other than nausea (9 SFX-01 (16.7%), 1 placebo (2.0%)). SFN, SFN-glutathione and SFN-N-acetyl-cysteine AUC last were 16.2, 277 and 415 h × ng/ml. Plasma SFN was higher in GSTT1 null individuals ( t = 2.40, p = 0.023). CSF levels were low with many samples below the lower limit of quantification and predicted by the CSF/serum albumin ratio ( R 2 = 0.182, p = 0.039). There was no difference in CSF haptoglobin (1.981 95%CI 0.992–3.786, p = 0.052) or malondialdehyde (1.12 95%CI 0.7477–1.687, p = 0.572) or middle cerebral artery flow velocity (1.04 95%CI 0.903–1.211, p = 0.545) or functional outcome (mRS 1.647 95%CI 0.721–3.821, p = 0.237, SAHOT 1.082 95%CI 0.464–2.525, p = 0.855). SFX-01 is safe and effective for the delivery of SFN in acutely unwell patients. SFN penetrated CSF less than expected and did not reduce large vessel vasospasm or improve outcome. Trial registration: NCT02614742 clinicaltrials.gov.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Subarachnoid HemorrhageSulfoxidesIsothiocyanatesHumansMiddle AgedMaleFemaleAdultDouble-Blind MethodAgedAged, 80 and overYoung AdultTreatment OutcomeAdolescentVasospasm, Intracranial

Stichwörter der Autor:innen

HaptoglobinNrf2PharmacokineticsRandomised clinical trialSubarachnoid haemorrhageSulforaphane

Substanzen

SulfoxidesIsothiocyanatessulforaphane

Autor:innen und Institutionen

  • Neurosurgery, University Hospital Southampton, Southampton, UK.
  • Clinical Neurosciences, Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.
  • Neuro Intensive Care, Royal Infirmary of Edinburgh, Edinburgh, UK.
  • Neurosurgery, Royal London Hospital, London, UK.
  • Medical Physics, University Hospital Southampton, Southampton, UK.
  • Evgen Pharma, Nether Alderley, UK.

Förderung

  • Evgen Pharma

Zitieren

APA

Zolnourian, A., Garland, P., Holton, P., Arora, M., Rhodes, J., Uff, C., Birch, T., Howat, D., Franklin, S., Galea, I., & Bulters, D. (2025). A Randomised Controlled Trial of SFX-01 After Subarachnoid Haemorrhage — The SAS Study. Translational Stroke Research. https://doi.org/10.1007/s12975-024-01278-1

Vancouver

Zolnourian A, Garland P, Holton P, Arora M, Rhodes J, Uff C, et al. A Randomised Controlled Trial of SFX-01 After Subarachnoid Haemorrhage — The SAS Study. Translational Stroke Research. 2025. doi:10.1007/s12975-024-01278-1

BibTeX
@article{Zolnourian2025,
  author = {Zolnourian, Ardalan and Garland, Patrick and Holton, Patrick and Arora, Mukul and Rhodes, Jonathan and Uff, Christopher and Birch, Tony and Howat, David and Franklin, Stephen and Galea, Ian and Bulters, Diederik},
  title = {A Randomised Controlled Trial of SFX-01 After Subarachnoid Haemorrhage — The SAS Study},
  journal = {Translational Stroke Research},
  year = {2025},
  doi = {10.1007/s12975-024-01278-1}
}
Kostenlos starten →